Pharmacological Effects of Pascoflair® on Brain Activity in Patients Suffering From Test Anxiety

Stress Clinical Trial

Official title:

Proof of Effectiveness of Pascoflair Using Qantitative Measurement of Electric Brain Activity During Examination Stress in 40 Subjects Suffering From Test Anxiety. A Double-blind, Randomized, Placebo-controlled, 2-armed, Phase IV Study in Parallel Design.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05049447
• Other study ID #: 200S14PF
• Status: Completed
• Phase: Phase 4
• Start date: May 2015
• Est. completion date: August 2015

Study information

• Verified date: September 2021
• Source: Pascoe Pharmazeutische Praeparate GmbH
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Proof of effectiveness of Pascoflair using qantitative measurement of electric brain activity during examination stress in 40 subjects suffering from test anxiety. A double-blind, randomized, placebo-controlled, 2-armed, Phase IV study in parallel design.

Description:

Anxiolytic effects of PASCOFLAIR® shall be tested in subjects suffering from test anxiety after single intake by aid of a newly developed, validated method consisting of a combination of eye tracking (following glances) with neurocode tracking (quantitative EEG with a time resolution of 364 ms).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: August 2015
• Est. primary completion date: August 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• Healthy male and female subjects.

• Age between 18 and 40 years (both included).

• Anxiety questionnaire PAF (pre-selection of subjects) - values above T> 60 are regarded as conclusive.

• Inconclusive case history and diagnosis.

• Subject must be capable of giving informed consent.

• Acceptance of written consent to participate in the study after education in written and oral form (informed consent).

Exclusion Criteria:

• Acute or chronic disease with an impact on the study, which becomes obvious by case history or clinical examination.

• Clinically relevant pathological findings from clinical and laboratory findings.

• Presence of clinically relevant pathological EEG features or artifact-free portion of the screening EEG <30%.

• Clinically relevant allergic symptoms.

• Detection of alcohol at the time of initial examination (day SC) or on study day A (positive alcohol test) or by case history.

• Detection of drugs (positive drug test) at the time of initial examination (day SC).

• Consumption of clinically relevant medication during last fourteen days before and during the active study period based on the notification of the subject or his case history.

• Consumption of medication with primarily central action (i.e. psychotropic drugs or centrally acting antihypertensives).

• Known intolerance / hypersensitivity (allergy) to plant derived extracts (Passion flower dry extract) or any of the ingredients of the investigational product (anamnestic).

• Presence of a rare, genetic disease such as fructose intolerance, glucosegalactose malabsorption or sucrase-isomaltase deficiency (anamnestic).

• BMI (Body Mass Index) <18 or> 32.

• Consumption of unusual quantities or misuse of coffee (more than 4 cups a day), tea (more than 4 cups a day) or tobacco (more than 20 cigarettes per day).

• Smoking on day of A.

Related Conditions & MeSH terms

• Anxiety Disorders
• Brain Activity
• Stress
• Test Anxiety

Intervention

Drug:
• Pascoflair
1 x 2 tablets (single-dose)

Other:
• Placebo
1 x 2 tablets (single-dose)

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Pascoe Pharmazeutische Praeparate GmbH	NeuroCode AG

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Comparison of verum and placebo Beta 1 power	Comparison of verum and placebo efficacy is performed on electric power in 17 different brain regions within six frequency ranges defined as target parameters in the presence of different stress inducing cognitive tests or exciting video scenes	day A (treatment day) - 1 day
Secondary	Tolerability in a 4- Point scale	Tolerability in a 4- Point scale (very good, good, moderately, poor)	Final examination (day AB) -1 day
Secondary	Correlation between questionnaire items and spectral EEG power with regard to different frequency ranges.	Correlation between questionnaire items and spectral EEG power with regard to different frequency ranges.	Final examination - 1 day